Non-benzoquinone geldanamycin analogs trigger various forms of death in human breast cancer cells

BACKGROUND: Hsp90 proteins are important therapeutic targets for many anti-cancer drugs in clinical trials. Geldanamycin (GA) was identified as the first natural inhibitor of Hsp90, increasing evidence suggests that GA was not a good choice for clinical trials. In this study, we investigated two new...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:J Exp Clin Cancer Res
Asıl Yazarlar: Zhang, Zhirui, Li, Hong-Mei, Zhou, Can, Li, Qixiang, Ma, Linyan, Zhang, Zixuan, Sun, Yiming, Wang, Lirong, Zhang, Xudong, Zhu, Bing, Hong, Young-Soo, Wu, Cheng-Zhu, Liu, Hao
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: BioMed Central 2016
Konular:
Research
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5034425/
https://ncbi.nlm.nih.gov/pubmed/27658586
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-016-0428-6
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller